TBPH Theravance Biopharma
- 9.460
- +0.090+0.96%
- 9.620
- +0.160+1.69%
Theravance Biopharma News
Theravance Biopharma (TBPH.US) was first covered by BTIG and given a buy rating, with a target price of $21.00.
Theravance Biopharma Analyst Ratings
Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma
Positive Financial Trajectory and Future Prospects Prompt Buy Rating for Theravance Biopharma
Promising Growth and Profitability Prospects: A Buy Rating for Theravance Biopharma
Hold Rating on Theravance Biopharma Amidst Steady Growth and Positive Future Expectations
Analysts Are Bullish on These Healthcare Stocks: Theravance Biopharma (TBPH), BioMarin Pharmaceutical (BMRN)
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), Arcturus Therapeutics (ARCT) and Poseida Therapeutics (PSTX)
HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
Theravance Biopharma Analyst Ratings
SVB Securities Remains a Buy on Theravance Biopharma (TBPH)
HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), ANI Pharmaceuticals (ANIP) and Theravance Biopharma (TBPH)
SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)
HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $19 Price Target
SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating
Theravance Biopharma Analyst Ratings
SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14
Robert W. Baird Reaffirms Their Hold Rating on Theravance Biopharma (TBPH)
HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating
Analysis
Price Target
No Data
